EWA
STLN

EverSource Wealth Advisors’s Starling Oncology Institute, Inc. Common Stock STLN Stock Holding History

EverSource Wealth Advisors’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$76 Buy
14
+1
+8% +$4 ﹤0.01% 4329
2026
Q1 		$40 Buy
+13
New +$40 ﹤0.01% 4333

Other funds holding STLN

Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
KWA
Kingswood Wealth Advisors San Diego, California $2.48B AUM 36.19% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return
WPC
White Pine Capital Bloomington, Minnesota $423M AUM 67.01% 1-Year Est. Return
TC
T3 Companies New York $93.7M AUM
SOW
State of Wyoming Cheyenne, Wyoming $989M AUM 52.24% 1-Year Est. Return
FCG
Fielder Capital Group Nashville, Tennessee $462M AUM 37.71% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return

EverSource Wealth Advisors's STLN Position: Q2 2026 in Review

EverSource Wealth Advisors increased its Starling Oncology Institute, Inc. Common Stock (STLN) stake by 7.7% in Q2 2026, buying an estimated $4 and bringing the position to 14 shares worth $76. The position accounts for ﹤0.01% of the portfolio, ranked #4329.

EverSource Wealth Advisors first reported a position in STLN in Q1 2026 and has held it in 2 quarters since. 30 funds tracked by Wall St. Rank hold STLN as of Q2 2026.

  • EverSource Wealth Advisors held 14 shares of Starling Oncology Institute, Inc. Common Stock worth $76 as of Q2 2026.
  • EverSource Wealth Advisors bought 1 Starling Oncology Institute, Inc. Common Stock share in Q2 2026, an estimated $4.
  • Starling Oncology Institute, Inc. Common Stock made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q2 2026, its #4329 holding.
  • EverSource Wealth Advisors first reported a position in Starling Oncology Institute, Inc. Common Stock in Q1 2026 and has held it in 2 quarters since.
  • 30 funds tracked by Wall St. Rank held Starling Oncology Institute, Inc. Common Stock as of Q2 2026.

Based on EverSource Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.